According to the latest gene-editing clinical trials report, CRISPER is on the go to join mainstream medicine. Casgevy, the first CRISPR-based therapy to receive FDA approval, remains the standard-bearer for gene editing in medicine. Approved in December 2023 for sickle cell disease and subsequently for beta-thalassemia, it demonstrated that CRISPR could move from the lab to the clinic. In 2026, that single approval has grown into a sprawling pipeline of clinical trials spanning cancer, autoimmune diseases, and rare genetic conditions.
The FDA has also introduced a new regulatory pathway designed to cut red tape for bespoke gene therapies targeting rare diseases, a move that could accelerate the timeline for CRISPR-based treatments still in development. Meanwhile, CRISPR Therapeutics and competing firms are advancing multiple candidates through mid- and late-stage trials, with a focus on inherited blood disorders and oncology applications.
The question is no longer whether gene editing works. It does, at least for the conditions tested so far. The question is whether the clinical infrastructure, manufacturing capacity, and pricing models can scale to meet the demand that these therapies will generate.